Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors is a research paper published in Cancer Medicine (2024). On theSindex it has a DataRank of 0.418. It has been cited 8 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.0885
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
University of Texas MD Anderson Cancer Center
Grant: UM1Award#UM1CA186688
NCI NIH HHS
Grant: UM1 CA186688
National Cancer Institute
Fields of Study
MeSH Terms
Keywords